Abstract
Over the past decade, the use of β-blockers has transformed the management and prognosis of patients with heart failure (HF). A post hoc analysis of the SENIORS study now raises questions about the validity of a composite 'ischemic' end point that includes sudden death in trials of β-blocker therapy for patients with HF.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
